BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Biotech Entrepreneur Ramaswamy Announces Presidential Run

  Vivek Ramaswamy, the founder of Roivant Sciences, is officially running for president, the GOP hopeful announced Tuesday.

  February 14, 2023

   · 

  2 min read

   · 

  Lisa Munger
• 

  Policy

  Pregnant Workers Fairness Act Evens Playing Field for Life Sciences Employees

  The Pregnant Workers Fairness Act (PWFA) has been praised by many in the life sciences who see it as a step forward in protecting the rights of pregnant employees.

  February 14, 2023

   · 

  4 min read

   · 

  Lisa Munger
• 

  Biopharma Execs Adopt Creative Mindset at BIO CEO

  As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession.

  February 14, 2023

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Enveda’s Matured Platform Drives Toward Three INDs in 2023

  Enveda’s primary R&D efforts will focus on inflammation, fibrosis and neurosensory biology within the GI, dermatology and pulmonary therapeutic areas.

  February 14, 2023

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Drug Development

  FDA Rejects Soligenix’s Lymphoma Candidate

  The FDA has rejected Soligenix’s NDA for HyBryte (synthetic hypericin), a therapeutic developed to treat early-stage cutaneous T-cell lymphoma.

  February 14, 2023

   · 

  1 min read

   · 

  Rosemary Scott
• 

  Business

  GSK Abandons COVID-19 Collaboration with Vir

  The COVID-19 research collaboration between Vir Biotechnology and GSK has largely come to an end, as Vir announced Monday it would be going it alone or with other partners.

  February 14, 2023

   · 

  1 min read

   · 

  Hayleigh Evans
• 

  Business

  John Reed Jumps Ship at Sanofi to Helm J&J’s R&D

  Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D.

  February 14, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Biotech Bay

  Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis

  Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has submitted a supplemental New Drug Application (sNDA) for LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC).

  February 14, 2023

   · 

  8 min read
• Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing

  Altamira Therapeutics Ltd. (Nasdaq:CYTO) today announced that data from three clinical studies with the Company’s Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Antonio, TX.

  February 14, 2023

   · 

  5 min read
• Biotech Beach

  Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

  Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

  February 14, 2023

   · 

  7 min read